Boston Scientific announced positive data from a trial of its Agent drug-coated balloon (DCB). The Marlborough, Massachusetts-based company presented its results at the Transcatheter Cardiovascular Therapeutics (TCT) meeting. Data demonstrated statistical superiority for Agent compared to uncoated balloon angioplasty. AGENT IDE evaluated the safety and effectiveness of using a DCB to treat coronary in-stent restenosis […]
TCT 2023
Recor Medical presents more data supporting its renal denervation system
Otsuka Medical Devices’ Recor Medical announced another set of positive study results for its Paradise ultrasound renal denervation (uRDN) system. A combined analysis of six-month follow-up data from three RADIANCE global studies evaluated Paradise as a hypertension treatment. The analysis demonstrated maintained blood pressure (BP) reduction following treatment with uRDN compared to sham. It also […]
PCI guidance tech from Philips delivers positive study results
Philips today announced study results supporting its instant wave-free ratio (iFR) in guiding percutaneous coronary intervention (PCI). Amsterdam-based Philips offers iFR as a pressure-derived index to assess coronary blockages during interventional procedures. iFR avoids the use of hyperemic agents — drugs that maximize blood flow but can impact the patient experience. Dr. Matthias Götberg presented […]
The biggest cardiovascular stories from TCT 2023
Every year, some of the biggest names in cardiovascular technologies come together in one place for TCT. This year’s 35th edition of the Transcatheter Cardiovascular Therapeutics annual scientific symposium was no different in San Francisco. Usual suspects like Medtronic and Abbott released data covering a range of products, while other big names like Edwards, GE […]
Abbott has positive data for Esprit drug-eluting resorbable scaffold
Abbott today announced data supporting its Esprit BTK everolimus-eluting resorbable scaffold system. The company designed Esprit BTK to treat people with chronic limb-threatening ischemia (CLTI), a severe stage of peripheral artery disease (PAD). Abbott said its LIFE-BTK trial met both of its primary safety and effectiveness endpoints. It demonstrated the reduction of disease progression and […]
Study backs left atrial appendage occlusion device from Conformal Medical
Conformal Medical announced positive one-year results from an early feasibility study of its left atrial appendage occlusion (LAAO) device. Nashua, New Hampshire-based Conformal shared the data at the 35th Transcatheter Cardiovascular Therapeutics (TCT) in San Francisco. Dr. William Gray presented the “Conformal CLAAS LAAO Device EFS 1-Year TEE Follow-Up.” “I am pleased to report that […]
5-year data supports Edwards Lifesciences’ Sapien 3 TAVR
Edwards Lifesciences announced new data demonstrating continued positive outcomes with its Sapien 3 transcatheter aortic valve replacement (TAVR). Results from the PARTNER 3 trial showed continued low rates of all-cause mortality, disabling stroke and rehospitalization at five years. Edwards presented the data at the 35th Transcatheter Cardiovascular Therapeutics (TCT) in San Francisco. It simultaneously published […]
Abbott reports positive TriClip, MitraClip data
Abbott announced positive data for two of its minimally invasive heart devices for treating mitral and tricuspid valve disease. Results from the TRILUMINATE pivotal trial reinforced the safety and effectiveness of the TriClip system. TriClip, a transcatheter edge-to-edge repair (TEER) system, treats patients with symptomatic, severe tricuspid regurgitation (TR). Abbott also shared data from the […]
Medtronic Evolut TAVR outperforms surgical valve replacement in study
Medtronic today announced positive four-year results from a trial of its Evolut transcatheter aortic valve replacement (TAVR) system. Evolut TAVR demonstrated “exceptional outcomes and sustained valve performance,” Medtronic says. It showed significantly better hemodynamics than surgical aortic valve replacement (SAVR). The company presented the data at the 35th Transcatheter Cardiovascular Therapeutics (TCT) conference in San […]
Slow and steady wins the race: JenaValve aims to offer new option for aortic regurgitation patients
The Munich-based startup JenaValve is a bit like the tortoise, with a slow and steady approach to transcatheter aortic valve replacement (TAVR) device development. At the Transcatheter Cardiovascular Therapeutics (TCT) conference today, Dr. Vinod Thourani, co-principal investigator of the ALIGN-AR study, jokingly compared the company’s approach to a “nice bottle of wine” that gets better […]
Medtronic has positive Intrepid TMVR data
Medtronic shared positive data from a study of its Intrepid transcatheter mitral valve replacement (TMVR). The medtech giant presented one-year results from the Intrepid early feasibility study at TCT 2023. It simultaneously published the data in JACC: Cardiovascular Intervention. Medtronic says the study demonstrated the early benefits of the Intrepid TMVR-transfemoral system, maintained up to […]
